Biogen Increases Profit Potential on Investigational Alzheimer's Disease Treatment Aducanumab …

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) announced today that it has increased the profit
potential on aducanumab, its Phase 3 investigational treatment
for early Alzheimer’s disease, by reducing the potential royalty payment
on potential commercial sales of aducanumab to Neurimmune Holding AG. In
exchange for a 15 percent reduction in the previously negotiated royalty
rates, Biogen agreed to make a one-time $150 million payment to
Neurimmune Holding AG.

Biogen licensed the worldwide rights to aducanumab from Neurimmune
Holding AG in 2007 and is responsible for its development and the

“This amended agreement with Neurimmune improves aducanumab’s potential
value to Biogen as we pursue our strategic goal of leadership in
Alzheimer’s disease,” said Michel Vounatsos, chief executive officer of
Biogen. “We are pleased with our ongoing collaboration with Neurimmune
in Alzheimer’s and other neurodegenerative disorders.”

As part of this amended agreement, Biogen also has an option to further
reduce the royalty owed on potential commercial sales of aducanumab by
an additional 5 percent in exchange for an additional one-time $50
million payment to Neurimmune Holding AG.

About Aducanumab

Aducanumab (BIIB037) is an investigational
compound being developed for the treatment of early Alzheimer’s disease.
Aducanumab is a human recombinant monoclonal antibody (mAb) derived from
a de-identified library of B cells collected from healthy elderly
subjects with no signs of cognitive impairment or cognitively impaired
elderly subjects with unusually slow cognitive decline using
Neurimmune’s technology platform called Reverse Translational Medicine
(RTM). Biogen licensed aducanumab from Neurimmune under a collaborative
development and license agreement.

Aducanumab is thought to target aggregated forms of beta amyloid
including soluble oligomers and insoluble fibrils which can form into
amyloid plaque in the brain of Alzheimer’s disease patients. Based on
pre-clinical and Phase 1b data to date, treatment with aducanumab has
been shown to reduce amyloid plaque levels.

In August 2016 aducanumab was accepted into the European Medicines
Agency’s PRIME program. In September 2016, the U.S. Food and Drug
Administration accepted aducanumab into its Fast Track program and in
April 2017 aducanumab was accepted into the Japanese Ministry of Health,
Labour and Welfare’s (MHLW) Sakigake Designation System.

About Biogen

At Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one of
the world’s first global biotechnology companies by Charles Weissman and
Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has
the leading portfolio of medicines to treat multiple sclerosis; has
introduced the first and only approved treatment for spinal muscular
atrophy; and is focused on advancing neuroscience research programs in
Alzheimer’s disease and dementia, neuroimmunology, movement disorders,
neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute
neurology. Biogen also manufactures and commercializes biosimilars of
advanced biologics. We routinely post information that may be important
to investors on our website at
To learn more, please visit
and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Biogen Safe Harbor Statement

This press release contains
forward-looking statements, including statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements relating to the anticipated benefits and
potential of our collaboration agreement with Neurimmune and the
potential of our commercial business and pipeline programs, including
aducanumab. These forward-looking statements may be accompanied by words
such as “aim,” “anticipate, “believe,” “could,” “estimate,” “expect,”
“forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will”,
and other words and terms of similar meaning. Drug development and
commercialization involve a high degree of risk, and only a small number
of research and development programs result in commercialization of a
product. Results in early stage clinical trials may not be indicative of
full results or results from later stage or larger scale clinical trials
and do not ensure regulatory approval. You should not place undue
reliance on these statements.

These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including without limitation, uncertainty as to whether the anticipated
benefits and potential of our collaboration agreement with Neurimmune
can be achieved; risks of unexpected costs or delays; uncertainty of
success in the development and potential commercialization of
aducanumab, which may be impacted by, among other things, unexpected
concerns that may arise from additional data or analysis, the occurrence
of adverse safety events, failure to obtain regulatory approvals in
certain jurisdictions, failure to protect and enforce our data,
intellectual property, and other proprietary rights and uncertainties
relating to intellectual property claims and challenges; and third party
collaboration risks. The foregoing sets forth many, but not all, of the
factors that could cause actual results to differ from our expectations
in any forward-looking statement. Investors should consider this
cautionary statement, as well as the risk factors identified in in
Biogen’s most recent annual or quarterly report and in other reports
Biogen has filed with the Securities and Exchange Commission. These
statements are based on our current beliefs and expectations and speak
only as of the date of this press release. We do not undertake any
obligation to publicly update any forward-looking statements, whether as
a result of new information, future developments or otherwise.

Read more

Leave A Comment

Your email address will not be published. Required fields are marked *